Personal information

No personal information available

Activities

Collapse all

Works (4)

Non‐adherence and non‐persistence with antiretroviral treatment in Belgium: A real‐world evaluation using a pharmacy database, 2018–2021

Pharmacoepidemiology and Drug Safety
2024-05 | Journal article
DOI: 10.1002/pds.5804
Contributors: Dieudonné Ilboudo; Patricia Mbouche; Agnès Sommet; Philippe Van Wilder; Fati Kirakoya‐Samadoulougou
Source: check_circle
Crossref

The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?

Pharmaceuticals
2021-04-10 | Journal article
DOI: 10.3390/ph14040352
Contributors: Philippe Van Wilder
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

Pharmaceuticals
2021-02-04 | Journal article
DOI: 10.3390/ph14020117
Contributors: Yannick Vandenplas; Steven Simoens; Philippe Van Wilder; Arnold G. Vulto; Isabelle Huys
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium

European Journal of Clinical Pharmacology
2019-07 | Journal article
DOI: 10.1007/s00228-019-02665-6
Contributors: Philippe Van Wilder; Magali Pirson; Alain Dupont
Source: check_circle
Crossref
How many people are using ORCID?